|
KMID : 0338419990140020015
|
|
The Korean Journal of Internal Medicine
1999 Volume.14 No. 2 p.15 ~ p.19
|
|
|
Imipenem-Cilastatin versus Sulbactam-Cefoperazone plus Amikacin in the Initial Treatment of Febrile Neutropenic Cancer Patients
|
|
Ozgur Ozyilkan/Ozgur OZYILKAN
UlKu YAL INTA/Sezgin BA KAN
|
|
|
Abstract
|
|
|
|
The treatment of infectious complications in cancer patients has evolved as a consequence of the developments in the chemotherapy of cancer patients. In this prospective, randomized study, we compared imipenem-cilastatin and sulbactam-cefoperazone with amikacin in the empiric therapy of febrile neutropenic (<1000/mm3) patients with liquids and solid tumours. Of 30 evaluable episodes, 15 were treated with imipenem-cilastatin and 15 were treated with sulbactam-cefoperazone plus amikacin. 73% of episodes were culture-positive; gram-positive pathogens accounted for 62% of the isolates. Bacteremia was the most frequent site of infection. The initial clinical response rate for both regimens was 60% (p>0.05). No major adverse effects occurred. This study demonstrated that imipenem-cilastatin monotherapy and combination therapy of sulbactam-cefoperazone plus amikacin were equally effective empiric therapy for febrile granulocytopenic cancer patients.
|
|
|
KEYWORD
|
|
|
Imipenem-Cilastatin, Sulbactam-Cefoperazone, Amikacin, Neutropenic fever,
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
    
|